Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Paused · Phase 2

Conditions studied: Progressive Glioblastoma, Recurrent Glioblastoma

In brief

This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid and may kill tumor cells. Giving relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma.

Key facts

Study ID

NCT06325683

Run by

National Cancer Institute (NCI)

People needed

184

Starts

2024-11-08

Expected to finish

2028-07-15

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-proven glioblastoma (World Health Organization [WHO] 2021 criteria)
• Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO) criteria
• No IDH mutation (IDH1 R132H negative by immunohistochemistry [IHC] or sequencing)
• Patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide
• No prior therapies except radiation, surgery, temozolomide, Tumor Treating Fields (TTFields), and/or Gliadel wafers (placed during the first surgery at diagnosis of glioblastoma multiforme [GBM]). Prior radiation therapy, TTFields, or placement of Gliadel wafers must be completed at least 2 weeks prior to registration. Prior temozolomide must be completed at least 3 weeks prior to registration
• No prior use of nivolumab or other anti-PD1 agents
• Patients must be neurologically stable off corticosteroids for at least 5 days prior to registration
• Age: ≥ 18 years
• Karnofsky Performance Status: ≥ 60% (i.e. patient must be able to care for themselves with occasional help from others)
• Absolute lymphocyte count (ALC): ≥ 1000/mm\^3
• Absolute neutrophil count (ANC): ≥ 1500/mm\^3
• Platelet count: ≥ 100,000/mm\^3
• Hemoglobin: ≥ 9.0 g/dL
• Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT): ≤ 1.5 x upper limit of normal (ULN)
• Total bilirubin: < 2.0 x ULN (Except for patients with Gilbert's syndrome, who must have direct bilirubin < 2.0 x ULN)
• Aspartate aminotransferase (AST) / alanine aminotransferase (ALT): < 3.0 x ULN
• Calculated (calc.) creatinine clearance (CrCl): ≥ 50 mL/min
• Calculated by Cockcroft-Gault equation
• Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done within 14 days prior to registration is required
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
• No active brain metastases or leptomeningeal disease
• HIV: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
• Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
• Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
• No known medical condition causing an inability to swallow oral formulations of agents

Where it is running

• Sutter Auburn Faith Hospital — Auburn, California, United States
• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• Kaiser Permanente Dublin — Dublin, California, United States
• Kaiser Permanente-Fremont — Fremont, California, United States
• Kaiser Permanente Fresno Orchard Plaza — Fresno, California, United States
• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California, United States
• UC San Diego Moores Cancer Center — La Jolla, California, United States
• City of Hope Antelope Valley — Lancaster, California, United States
• City of Hope at Long Beach Elm — Long Beach, California, United States
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Kaiser Permanente- Modesto MOB II — Modesto, California, United States
• Kaiser Permanente-Modesto — Modesto, California, United States
• Kaiser Permanente-Oakland — Oakland, California, United States
• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California, United States
• Palo Alto Medical Foundation Health Care — Palo Alto, California, United States
• Stanford Cancer Institute Palo Alto — Palo Alto, California, United States
• Kaiser Permanente- Marshall Medical Offices — Redwood City, California, United States
• Kaiser Permanente-Roseville — Roseville, California, United States
• Sutter Roseville Medical Center — Roseville, California, United States
• Kaiser Permanente Downtown Commons — Sacramento, California, United States
• Sutter Medical Center Sacramento — Sacramento, California, United States
• Kaiser Permanente-South Sacramento — Sacramento, California, United States
• Kaiser Permanente-San Diego Zion — San Diego, California, United States
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.